Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNYSE:RCUSNASDAQ:SLDBNASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.85+4.9%$4.39$3.21▼$8.06$921.13M0.764.46 million shs5.24 million shsRCUSArcus Biosciences$9.21+3.1%$8.27$6.50▼$18.98$974.67M0.88862,284 shs1.48 million shsSLDBSolid Biosciences$3.54+10.3%$3.11$2.41▼$10.37$274.40M2.321.09 million shs2.27 million shsWVEWave Life Sciences$6.25+4.0%$6.57$4.25▼$16.74$963.34M-0.921.30 million shs1.03 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%-6.30%-9.93%-26.77%-45.77%RCUSArcus Biosciences0.00%-0.72%-1.54%-14.72%-40.41%SLDBSolid Biosciences0.00%+13.88%-25.75%-37.50%-61.26%WVEWave Life Sciences0.00%+2.18%-24.94%-39.50%-1.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.5976 of 5 stars4.53.00.04.42.22.50.6RCUSArcus Biosciences2.6384 of 5 stars4.51.00.00.02.42.50.0SLDBSolid Biosciences3.7549 of 5 stars4.61.00.00.02.93.31.3WVEWave Life Sciences4.3581 of 5 stars3.50.00.04.84.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39169.84% UpsideRCUSArcus Biosciences 2.91Moderate Buy$25.67178.83% UpsideSLDBSolid Biosciences 3.23Buy$14.90320.90% UpsideWVEWave Life Sciences 3.00Buy$21.17238.67% UpsideCurrent Analyst Ratings BreakdownLatest SLDB, RCUS, ARDX, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/13/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.55N/AN/A$0.73 per share5.27RCUSArcus Biosciences$141M6.91N/AN/A$6.17 per share1.49SLDBSolid Biosciences$8.09M33.92N/AN/A$6.27 per share0.56WVEWave Life Sciences$104.94M9.18N/AN/A$0.40 per share15.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A12.42N/A-11.73%-24.87%-10.51%7/30/2025 (Estimated)RCUSArcus Biosciences-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%8/14/2025 (Estimated)SLDBSolid Biosciences-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)WVEWave Life Sciences-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%8/14/2025 (Estimated)Latest SLDB, RCUS, ARDX, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/8/2025Q1 2025WVEWave Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million3/4/2025Q4 2024WVEWave Life Sciences-$0.17$0.17+$0.34$0.17$25.60 million$83.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/AWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31RCUSArcus Biosciences0.085.245.24SLDBSolid BiosciencesN/A7.857.85WVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%RCUSArcus Biosciences92.89%SLDBSolid Biosciences81.46%WVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%RCUSArcus Biosciences12.30%SLDBSolid Biosciences1.90%WVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableRCUSArcus Biosciences500105.89 million80.26 millionOptionableSLDBSolid Biosciences10077.52 million35.05 millionOptionableWVEWave Life Sciences240154.13 million108.14 millionOptionableSLDB, RCUS, ARDX, and WVE HeadlinesRecent News About These CompaniesUniversal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)June 2 at 4:41 AM | marketbeat.comNuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 31 at 3:37 AM | marketbeat.comWave Life Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LPMay 29, 2025 | marketbeat.comBank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 29, 2025 | marketbeat.comWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical OfficerMay 28, 2025 | globenewswire.comPolar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 28, 2025 | marketbeat.com845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLCMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 20, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust CorpMay 19, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comPolar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 18, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.May 17, 2025 | marketbeat.comMPM Bioimpact LLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for WVE Increased by Cantor FitzgeraldMay 16, 2025 | marketbeat.comMaven Securities LTD Sells 680,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 15, 2025 | marketbeat.comB. Riley Has Pessimistic Outlook of WVE FY2029 EarningsMay 14, 2025 | marketbeat.comFY2028 Earnings Estimate for WVE Issued By WedbushMay 14, 2025 | marketbeat.comIs Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | msn.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by The Manufacturers Life Insurance CompanyMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLDB, RCUS, ARDX, and WVE Company DescriptionsArdelyx NASDAQ:ARDX$3.85 +0.18 (+4.90%) Closing price 04:00 PM EasternExtended Trading$3.85 0.00 (0.00%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Arcus Biosciences NYSE:RCUS$9.20 +0.28 (+3.08%) Closing price 03:59 PM EasternExtended Trading$8.96 -0.25 (-2.72%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Solid Biosciences NASDAQ:SLDB$3.54 +0.33 (+10.28%) Closing price 04:00 PM EasternExtended Trading$3.55 +0.01 (+0.28%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Wave Life Sciences NASDAQ:WVE$6.25 +0.24 (+3.99%) Closing price 04:00 PM EasternExtended Trading$6.32 +0.08 (+1.20%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
